Effect of cetrorelix dose on premature LH surge during ovarian stimulation

Yu Hung Lin, K. M. Seow, H. J. Chen, B. C. Hsieh, L. W. Huang, C. R. Tzeng, Jiann-Loung Hwang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Previous studies have shown that ovarian stimulation with clomiphene citrate (CC), human menopausal gonadotrophin (HMG), and multiple-dose gonadotrophin-releasing hormone (GnRH) antagonist is associated with a high rate of premature LH surge. This study assessed whether administration of the GnRH antagonist cetrorelix at an incremental dose or at a high dose (0.5mg) from the start could prevent premature LH surge. Couples with male factor or unexplained infertility who were going to undergo intrauterine insemination were randomized into two stimulation protocols. All women were stimulated with CC and HMG. In protocol A, cetrorelix was given at 0.25 mg per day when the leading follicles reached 14 mm, and increased to 0.5 mg when the leading follicles were 16 mm. With protocol B, cetrorelix was given at 0.5 mg per day when the leading follicles reached 14 mm. The primary outcome measure was the incidence of premature LH surge. Premature LH surge occurred in 21.6% of patients undergoing protocol A, and in 18.9% of patients undergoing protocol B. Cetrorelix at incremental dose or at 0.5 mg per day does not prevent premature LH surges associated with the CC/ HMG/multiple-dose cetrorelix stimulation protocol.

Original languageEnglish
Pages (from-to)772-777
Number of pages6
JournalReproductive BioMedicine Online
Volume16
Issue number6
Publication statusPublished - Jun 2008

Fingerprint

Ovulation Induction
Menotropins
Clomiphene
Hormone Antagonists
Gonadotropin-Releasing Hormone
Insemination
Infertility
Outcome Assessment (Health Care)
cetrorelix
Incidence

Keywords

  • Cetrorelix
  • Clomiphene citrate
  • GnRH antagonist
  • Premature LH surge

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Lin, Y. H., Seow, K. M., Chen, H. J., Hsieh, B. C., Huang, L. W., Tzeng, C. R., & Hwang, J-L. (2008). Effect of cetrorelix dose on premature LH surge during ovarian stimulation. Reproductive BioMedicine Online, 16(6), 772-777.

Effect of cetrorelix dose on premature LH surge during ovarian stimulation. / Lin, Yu Hung; Seow, K. M.; Chen, H. J.; Hsieh, B. C.; Huang, L. W.; Tzeng, C. R.; Hwang, Jiann-Loung.

In: Reproductive BioMedicine Online, Vol. 16, No. 6, 06.2008, p. 772-777.

Research output: Contribution to journalArticle

Lin, YH, Seow, KM, Chen, HJ, Hsieh, BC, Huang, LW, Tzeng, CR & Hwang, J-L 2008, 'Effect of cetrorelix dose on premature LH surge during ovarian stimulation', Reproductive BioMedicine Online, vol. 16, no. 6, pp. 772-777.
Lin YH, Seow KM, Chen HJ, Hsieh BC, Huang LW, Tzeng CR et al. Effect of cetrorelix dose on premature LH surge during ovarian stimulation. Reproductive BioMedicine Online. 2008 Jun;16(6):772-777.
Lin, Yu Hung ; Seow, K. M. ; Chen, H. J. ; Hsieh, B. C. ; Huang, L. W. ; Tzeng, C. R. ; Hwang, Jiann-Loung. / Effect of cetrorelix dose on premature LH surge during ovarian stimulation. In: Reproductive BioMedicine Online. 2008 ; Vol. 16, No. 6. pp. 772-777.
@article{0f186561e2924962acf25a23c1cea50a,
title = "Effect of cetrorelix dose on premature LH surge during ovarian stimulation",
abstract = "Previous studies have shown that ovarian stimulation with clomiphene citrate (CC), human menopausal gonadotrophin (HMG), and multiple-dose gonadotrophin-releasing hormone (GnRH) antagonist is associated with a high rate of premature LH surge. This study assessed whether administration of the GnRH antagonist cetrorelix at an incremental dose or at a high dose (0.5mg) from the start could prevent premature LH surge. Couples with male factor or unexplained infertility who were going to undergo intrauterine insemination were randomized into two stimulation protocols. All women were stimulated with CC and HMG. In protocol A, cetrorelix was given at 0.25 mg per day when the leading follicles reached 14 mm, and increased to 0.5 mg when the leading follicles were 16 mm. With protocol B, cetrorelix was given at 0.5 mg per day when the leading follicles reached 14 mm. The primary outcome measure was the incidence of premature LH surge. Premature LH surge occurred in 21.6{\%} of patients undergoing protocol A, and in 18.9{\%} of patients undergoing protocol B. Cetrorelix at incremental dose or at 0.5 mg per day does not prevent premature LH surges associated with the CC/ HMG/multiple-dose cetrorelix stimulation protocol.",
keywords = "Cetrorelix, Clomiphene citrate, GnRH antagonist, Premature LH surge",
author = "Lin, {Yu Hung} and Seow, {K. M.} and Chen, {H. J.} and Hsieh, {B. C.} and Huang, {L. W.} and Tzeng, {C. R.} and Jiann-Loung Hwang",
year = "2008",
month = "6",
language = "English",
volume = "16",
pages = "772--777",
journal = "Reproductive BioMedicine Online",
issn = "1472-6483",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Effect of cetrorelix dose on premature LH surge during ovarian stimulation

AU - Lin, Yu Hung

AU - Seow, K. M.

AU - Chen, H. J.

AU - Hsieh, B. C.

AU - Huang, L. W.

AU - Tzeng, C. R.

AU - Hwang, Jiann-Loung

PY - 2008/6

Y1 - 2008/6

N2 - Previous studies have shown that ovarian stimulation with clomiphene citrate (CC), human menopausal gonadotrophin (HMG), and multiple-dose gonadotrophin-releasing hormone (GnRH) antagonist is associated with a high rate of premature LH surge. This study assessed whether administration of the GnRH antagonist cetrorelix at an incremental dose or at a high dose (0.5mg) from the start could prevent premature LH surge. Couples with male factor or unexplained infertility who were going to undergo intrauterine insemination were randomized into two stimulation protocols. All women were stimulated with CC and HMG. In protocol A, cetrorelix was given at 0.25 mg per day when the leading follicles reached 14 mm, and increased to 0.5 mg when the leading follicles were 16 mm. With protocol B, cetrorelix was given at 0.5 mg per day when the leading follicles reached 14 mm. The primary outcome measure was the incidence of premature LH surge. Premature LH surge occurred in 21.6% of patients undergoing protocol A, and in 18.9% of patients undergoing protocol B. Cetrorelix at incremental dose or at 0.5 mg per day does not prevent premature LH surges associated with the CC/ HMG/multiple-dose cetrorelix stimulation protocol.

AB - Previous studies have shown that ovarian stimulation with clomiphene citrate (CC), human menopausal gonadotrophin (HMG), and multiple-dose gonadotrophin-releasing hormone (GnRH) antagonist is associated with a high rate of premature LH surge. This study assessed whether administration of the GnRH antagonist cetrorelix at an incremental dose or at a high dose (0.5mg) from the start could prevent premature LH surge. Couples with male factor or unexplained infertility who were going to undergo intrauterine insemination were randomized into two stimulation protocols. All women were stimulated with CC and HMG. In protocol A, cetrorelix was given at 0.25 mg per day when the leading follicles reached 14 mm, and increased to 0.5 mg when the leading follicles were 16 mm. With protocol B, cetrorelix was given at 0.5 mg per day when the leading follicles reached 14 mm. The primary outcome measure was the incidence of premature LH surge. Premature LH surge occurred in 21.6% of patients undergoing protocol A, and in 18.9% of patients undergoing protocol B. Cetrorelix at incremental dose or at 0.5 mg per day does not prevent premature LH surges associated with the CC/ HMG/multiple-dose cetrorelix stimulation protocol.

KW - Cetrorelix

KW - Clomiphene citrate

KW - GnRH antagonist

KW - Premature LH surge

UR - http://www.scopus.com/inward/record.url?scp=45749086919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749086919&partnerID=8YFLogxK

M3 - Article

C2 - 18549685

AN - SCOPUS:45749086919

VL - 16

SP - 772

EP - 777

JO - Reproductive BioMedicine Online

JF - Reproductive BioMedicine Online

SN - 1472-6483

IS - 6

ER -